Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 14/20 | 0.66 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.61 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.58 |
| ▸ | IKBKB | O14920 | 4/20 | 0.58 |
| ▸ | CHUK | O15111 | 4/20 | 0.58 |
| ▸ | AKT1 | P31749 | 4/20 | 0.58 |
| ▸ | AKT2 | P31751 | 4/20 | 0.58 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30043510 | 1.00 | PADI4 (0.66) | PADI4MAPK10ASAH1IKBKBCHUK | |
| SCHEMBL16111883 | 0.92 | PADI4 (0.68) | PADI4MAPK10ASAH1IKBKBCHUK | |
| SCHEMBL16111884 | 0.92 | PADI4 (0.68) | PADI4MAPK10ASAH1IKBKBCHUK | |
| SCHEMBL19857810 | 0.90 | PADI4 (0.73) | PADI4MAPK10IKBKBCHUKAKT1 | |
| SCHEMBL19857811 | 0.90 | PADI4 (0.73) | PADI4MAPK10IKBKBCHUKAKT1 | |
| SCHEMBL245343 | 0.86 | PADI4 (0.68) | PADI4MAPK10ASAH1IKBKBCHUK | |
| SCHEMBL245342 | 0.86 | PADI4 (0.68) | PADI4MAPK10ASAH1IKBKBCHUK | |
| SCHEMBL23498282 | 0.86 | MAPK10 (0.81) | PADI4MAPK10ASAH1IKBKBCHUK | |
| SCHEMBL23498073 | 0.85 | PADI4 (0.48) | PADI4MAPK10ASAH1IKBKBCHUK | |
| SCHEMBL30044903 | 0.85 | PADI4 (0.48) | PADI4MAPK10ASAH1IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | TES PHARMA S.R.L. (IT) | 2023-02-16 | — | — | US | disclosed |
| WO-2021116999-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021116999-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | RAD51, BRCA1, FANCI | PADI4 4745/4885MAPK10 4223/4885ASAH1 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.